David B. Seder

David B. Seder

Auto-generated profile, based on publicly available information

David B. Seder

Maine Med Ctr, Dept Crit Care Serv, Portland, ME 04102 USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2016 in Neurocritical Care
Verified
Journal Article
Closed access
PDF file
HFHerbert I. Fried
Herbert I. Fried
BNBarnett R. Nathan
Barnett R. Nathan
ARA. Shaun Rowe
A. Shaun Rowe
JZJoseph M. Zabramski
Joseph M. Zabramski
NANorberto Andaluz
Norberto Andaluz
JSJeffrey M. Singh
Jeffrey M. Singh

14 November 2017 in Critical Care
Verified
Journal Article
Open access
PDF file
LPLauren E. Payne
Lauren E. Payne
DGDavid J. Gagnon
David J. Gagnon
RRRichard R. Riker
Richard R. Riker
DSDavid B. Seder
David B. Seder
EGElizabeth K. Glisic
Elizabeth K. Glisic
GFGilles L. Fraser
Gilles L. Fraser
Cefepime is a widely used antibiotic with neurotoxicity attributed to its ability to cross the blood–brain barrier and exhibit concentration-dependent ϒ-aminobutyric acid (GABA) antagonism. Neurotoxic symptoms include depressed consciousness, encephalopathy, aphasia, myoclonus, seizures, and coma. Data suggest that up to 15% of ICU patients treated with cefepime may experience these adverse effects. Risk factors include renal dysfunction, excessive dosing, preexisting brain injury, and elevated serum cefepime concentrations. We aimed to characterize the clinical course of cefepime neurotoxicity and response to interventions. A librarian-assisted search identified publications describing cefepime-associated neurotoxicity from January 1980 to February 2016 using the CINAHL and MEDLINE databases. Search terms included cefepime, neurotoxicity, encephalopathy, seizures, delirium, coma, non-convulsive status epilepticus, myoclonus, confusion, aphasia, agitation, and death. Two reviewers independently assessed identified articles for eligibility and used the Preferred Reporting Items for Systematic review and Meta-Analysis Protocols (PRISMA-P) for data reporting. Of the 123 citations identified, 37 (representing 135 patient cases) were included. Patients had a median age of 69 years, commonly had renal dysfunction (80%) and required intensive care (81% of patients with a reported location). All patients exhibited altered mental status, with reduced consciousness (47%), myoclonus (42%), and confusion (42%) being the most common symptoms. All 98 patients (73% of cohort) with electroencephalography had abnormalities, including non-convulsive status epilepticus (25%), myoclonic status epilepticus (7%), triphasic waves (40%), and focal sharp waves (39%). As per Food and Drug Administration (FDA)-approved dosing guidance, 48% of patients were overdosed; however, 26% experienced neurotoxicity despite appropriate dosing. Median cefepime serum and cerebrospinal fluid (CSF) concentrations were 45 mg/L (n = 21) and 13 mg/L (n = 4), respectively. Symptom improvement occurred in 89% of patients, and 87% survived to hospital discharge. The median delay from starting the drug to symptom onset was 4 days, and resolution occurred a median of 2 days after the intervention, which included cefepime discontinuation, antiepileptic administration, or hemodialysis. Cefepime-induced neurotoxicity is challenging to recognize in the critically ill due to widely varying symptoms that are common in ICU patients. This adverse reaction can occur despite appropriate dosing, usually resolves with drug interruption, but may require additional interventions such as antiepileptic drug administration or dialysis.

1 January 2018 in The Lancet Neurology
Verified
Journal Article
Open access
BCBruce C V Campbell
Bruce C V Campbell
MGMayank Goyal
Mayank Goyal
BMBijoy K Menon
Bijoy K Menon
DDDiederik W J Dippel
Diederik W J Dippel
ADAndrew M Demchuk
Andrew M Demchuk
JCJames Cunningham
James Cunningham
General anaesthesia (GA) during endovascular thrombectomy has been associated with worse patient outcomes in observational studies compared with patients treated without GA. We assessed functional outcome in ischaemic stroke patients with large vessel anterior circulation occlusion undergoing endovascular thrombectomy under GA, versus thrombectomy not under GA (with or without sedation) versus standard care (ie, no thrombectomy), stratified by the use of GA versus standard care. For this meta-analysis, patient-level data were pooled from all patients included in randomised trials in PuMed published between Jan 1, 2010, and May 31, 2017, that compared endovascular thrombectomy predominantly done with stent retrievers with standard care in anterior circulation ischaemic stroke patients (HERMES Collaboration). The primary outcome was functional outcome assessed by ordinal analysis of the modified Rankin scale (mRS) at 90 days in the GA and non-GA subgroups of patients treated with endovascular therapy versus those patients treated with standard care, adjusted for baseline prognostic variables. To account for between-trial variance we used mixed-effects modelling with a random effect for trials incorporated in all models. Bias was assessed using the Cochrane method. The meta-analysis was prospectively designed, but not registered. Seven trials were identified by our search; of 1764 patients included in these trials, 871 were allocated to endovascular thrombectomy and 893 were assigned standard care. After exclusion of 74 patients (72 did not undergo the procedure and two had missing data on anaesthetic strategy), 236 (30%) of 797 patients who had endovascular procedures were treated under GA. At baseline, patients receiving GA were younger and had a shorter delay between stroke onset and randomisation but they had similar pre-treatment clinical severity compared with patients who did not have GA. Endovascular thrombectomy improved functional outcome at 3 months both in patients who had GA (adjusted common odds ratio (cOR) 1·52, 95% CI 1·09-2·11, p=0·014) and in those who did not have GA (adjusted cOR 2·33, 95% CI 1·75-3·10, p<0·0001) versus standard care. However, outcomes were significantly better for patients who did not receive GA versus those who received GA (covariate-adjusted cOR 1·53, 95% CI 1·14-2·04, p=0·0044). The risk of bias and variability between studies was assessed to be low. Worse outcomes after endovascular thrombectomy were associated with GA, after adjustment for baseline prognostic variables. These data support avoidance of GA whenever possible. The procedure did, however, remain effective versus standard care in patients treated under GA, indicating that treatment should not be withheld in those who require anaesthesia for medical reasons. Medtronic.

1 January 2014 in Resuscitation
Verified
Journal Article
Closed access
RHRyan D. Hollenbeck
Ryan D. Hollenbeck
JMJohn A. McPherson
John A. McPherson
MMMichael R. Mooney
Michael R. Mooney
BUBarbara T. Unger
Barbara T. Unger
NPNainesh C. Patel
Nainesh C. Patel
KKKarl B. Kern
Karl B. Kern

1 July 2015 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
KKKarl B. Kern
Karl B. Kern
KLKapildeo Lotun
Kapildeo Lotun
NPNainesh Patel
Nainesh Patel
MMMichael R. Mooney
Michael R. Mooney
RHRyan D. Hollenbeck
Ryan D. Hollenbeck
DSDavid B. Seder
David B. Seder

1 August 2009 in Neurosurgery
Verified
Journal Article
Closed access
PDF file
ECEmmanuel Carrera
Emmanuel Carrera
JSJ. Michael Schmidt
J. Michael Schmidt
MOMauro Oddo
Mauro Oddo
LFLuis Fernandez
Luis Fernandez
JCJan Claassen
Jan Claassen
SMStephan A. Mayer
Stephan A. Mayer
OBJECTIVE. Transcranial Doppler (TCD) is widely used to monitor the temporal course of vasospasm after subarachnoid hemorrhage (SAH), but its ability to